Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan-Dirk Studt

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Transfusion|November 5, 2019
Impact of rivaroxaban plasma concentration on perioperative red blood cell lossAlexander Kaserer, Greta Emilia Kiavialaitis, Julia Braun, et al.
Blood Advances|September 22, 2021
Daratumumab for immune thrombotic thrombocytopenic purpuraJana van den Berg, Johanna A Kremer Hovinga, Claudia Pfleger, et al.
Research and Practice in Thrombosis and Haemostasis|May 4, 2026
Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-upRoman Schimmer, Jana van den Berg, Marissa Schraner, et al.
Transfusion|November 29, 2016
Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulationOliver M Theusinger, David Goslings, Jan-Dirk Studt, et al.
Blood|March 15, 2003
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsSara K Vesely, James N George, Bernhard Lämmle, et al.
Transfusion|November 27, 2012
Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet componentsJoerg-Peter Sigle, Laura Infanti, Jan-Dirk Studt, et al.
British Journal of Haematology|January 3, 2024
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumabRoman R Schimmer, Tabea Sutter, Adrian Bachofner, et al.
Journal of Clinical Medicine|April 28, 2023
Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care CenterAlexander Ring, Wolfgang Alexander Sieber, Jan-Dirk Studt, et al.
Blood|February 26, 2004
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twinsJan-Dirk Studt, Johanna A Kremer Hovinga, Radovan Radonic, et al.
Anesthesia and Analgesia|December 15, 2017
The Impact of Prehospital Tranexamic Acid on Blood Coagulation in Trauma PatientsPhilipp Stein, Jan-Dirk Studt, Roland Albrecht, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Transfusion|November 5, 2019
Impact of rivaroxaban plasma concentration on perioperative red blood cell lossAlexander Kaserer, Greta Emilia Kiavialaitis, Julia Braun, et al.
Blood Advances|September 22, 2021
Daratumumab for immune thrombotic thrombocytopenic purpuraJana van den Berg, Johanna A Kremer Hovinga, Claudia Pfleger, et al.
Research and Practice in Thrombosis and Haemostasis|May 4, 2026
Daratumumab for relapsed refractory immune thrombotic thrombocytopenic purpura: initial response and long-term follow-upRoman Schimmer, Jana van den Berg, Marissa Schraner, et al.
Transfusion|November 29, 2016
Quarantine versus pathogen-reduced plasma-coagulation factor content and rotational thromboelastometry coagulationOliver M Theusinger, David Goslings, Jan-Dirk Studt, et al.
Blood|March 15, 2003
ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patientsSara K Vesely, James N George, Bernhard Lämmle, et al.
Transfusion|November 27, 2012
Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet componentsJoerg-Peter Sigle, Laura Infanti, Jan-Dirk Studt, et al.
British Journal of Haematology|January 3, 2024
Successful management of refractory immune-mediated thrombotic thrombocytopenic purpura during pregnancy and delivery using the anti-VWF nanobody caplacizumabRoman R Schimmer, Tabea Sutter, Adrian Bachofner, et al.
Journal of Clinical Medicine|April 28, 2023
Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care CenterAlexander Ring, Wolfgang Alexander Sieber, Jan-Dirk Studt, et al.
Blood|February 26, 2004
Familial acquired thrombotic thrombocytopenic purpura: ADAMTS13 inhibitory autoantibodies in identical twinsJan-Dirk Studt, Johanna A Kremer Hovinga, Radovan Radonic, et al.
Anesthesia and Analgesia|December 15, 2017
The Impact of Prehospital Tranexamic Acid on Blood Coagulation in Trauma PatientsPhilipp Stein, Jan-Dirk Studt, Roland Albrecht, et al.
Pageof 6